Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927729 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL2007369 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3925251 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL2007366 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3925245 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL7069618 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3928640 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3928631 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL6062580 | 0.96 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL14376659 | 0.96 | TLR4 (1.00) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026097604-A1 | COMPOSITION AND DRUG-DEVICE COMBINATION PRODUCT FOR LOCAL TUMOR ADMINISTRATION, AND USE | 诺曼德美国有限责任公司 | 2026-05-15 | — | — | WO | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | claimed |
| US-20260115280-A1 | VACCINES | ADJUVANCE TECH INC (US) | 2026-04-30 | — | — | US | claimed |
| US-12582711-B2 | RNA-based adjuvant to enhance the immune response to vaccines and therapeutics | ImmuneSure LLC (US) | 2026-03-24 | — | — | US | claimed |
| US-20250367283-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2025-12-04 | — | — | US | claimed |
| CN-112672763-B | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2025-03-25 | — | — | CN | claimed |
| WO-2025043016-A2 | A UNIVERSAL VACCINE STRATEGY FOR CONFERRING PROTECTION AGAINST DIVERSE PATHOGENS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-02-27 | — | — | WO | claimed |
| US-20250041348-A1 | EXTRACELLULAR VESICLE THERAPY TO TREAT ORTHOPEDIC INJURY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2025-02-06 | — | — | US | claimed |
| WO-2025030027-A1 | EXTRACELLULAR VESICLE THERAPY TO TREAT ORTHOPEDIC INJURY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-02-06 | — | — | WO | claimed |
| EP-4487869-A2 | RNA ENCODING A TUMOR ANTIGEN | CureVac SE (DE) | 2025-01-08 | — | — | EP | claimed |
| CN-115151559-A | Staphylococcal peptides and methods of use | 扬森疫苗与预防公司 | 2022-10-04 | — | — | CN | claimed |
| WO-2022171681-A1 | HPV VACCINE MANUFACTURE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-08-18 | — | — | WO | claimed |
| EP-4038091-A1 | STAPHYLOCOCCUS PEPTIDES AND METHODS OF USE | Janssen Vaccines & Prevention B.V. (NL) | 2022-08-10 | — | — | EP | claimed |
| CN-114794017-A | Construction method of pemphigus vulgaris animal model | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2022-07-29 | — | — | CN | claimed |
| CN-108289902-B | Inhibitors of the mevalonate pathway as highly effective vaccine adjuvants | 清华大学 | 2022-05-20 | — | — | CN | claimed |
| WO-2022063858-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BIOSCIENCE SA (CH) | 2022-03-31 | — | — | WO | claimed |
| EP-3973986-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2022-03-30 | — | — | EP | claimed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | claimed |
| WO-2022020427-A1 | MICRONEEDLE IMMUNOTHERAPEUTIC MULTI-COMPONENT SYSTEM AND A METHOD FOR VACCINATION | MICRONEEDLES INC. (US) | 2022-01-27 | — | — | WO | claimed |
| EP-1385541-B1 | IMMUNOSTIMULANT COMPOSITIONS COMPRISING AN AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND QS-21 | CORIXA CORP (US) | 2008-06-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | TLR4 12/4885LY96 68/4885 |
| US-20250367283-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | TLR4 2624/4885LY96 1038/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | TLR4 18/4885LY96 119/4885 |
| US-20260115280-A1 | VACCINES | TLR9, TLR3, TLR7 | TLR4 6/4885LY96 37/4885 |
| US-12582711-B2 | RNA-based adjuvant to enhance the immune response to vaccines and therapeutics | METTL16, RBM28, RBM26 | TLR4 262/4885LY96 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.